Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 14, 2026, titled "Dr. Reddy s announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's has announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. over-the-counter (OTC) market. This product is the generic equivalent of Extra-Strength Pataday® Once Daily Relief, a well-known eye allergy brand. Being first-to-market means Dr. Reddy's is the first generic manufacturer to introduce this product after the brand lost its patent protection. The launch expands the company's OTC ophthalmology portfolio in its key U.S. market.
This is a positive development for shareholders, as first-to-market generic launches typically capture higher market share and better pricing before competition arrives. The move strengthens Dr. Reddy's U.S. generics business and adds a high-demand OTC product, potentially boosting revenue in the coming quarters.